Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Ypsomed expands collaboration with Ten23 Health on YpsoDose

Ypsomed and Ten23 Health are deepening their cooperation for the wearable injector YpsoDose. Ten23 Health has set up new assembly capacity, with qualification nearing completion. The partners now offer an integrated solution from development through sterile filling to assembly, making it easier for pharmaceutical companies to access an end-to-end supply chain for drug‑device combination products. » Mere på finanzen.net
UBS downgrade pushes Ypsomed stock down nearly 7%

UBS downgraded Ypsomed from "Buy" to "Neutral" and cut its price target from CHF 425 to CHF 400; the stock then fell about 6.9% to CHF 355.2 (intraday low CHF 345). The bank cites significantly worse prospects for the obesity drug CagriSema after head-to-head data, and cut its sales forecasts for CagriSema in diabetes by about 50%. UBS still sees growth potential in Ypsomed’s broader product pipeline but expects that lower CagriSema volumes cannot be fully offset in the mid term. The share drop is strictly company-specific and contrasted with a positive market performance that day. » Mere på de.investing.com
UBS downgrades Ypsomed to "Neutral" after Cagrisema setback

UBS has cut Ypsomed from "Buy" to "Neutral" and lowered the price target from 425 to 400 francs after Phase‑3 data for Cagrisema disappointed. UBS halved its peak sales potential for Cagrisema in type‑2 diabetes and reduced Ypsomed’s expected GLP‑1 product sales for 2029/30 by 10% to 255 million francs, which trims EPS forecasts for 2026–2029 by about 5% on average. The share fell roughly 6.7% intraday. UBS cites Novo Nordisk’s Capital Markets Day and the expected approval of Cagrisema in late 2026/early 2027 as the next catalysts. » Mere på de.investing.com
Ypsomed wins 14 new customer projects in first quarter

Ypsomed has started the 2026/27 fiscal year strongly, winning 14 new customer projects in the first quarter, exceeding the quarterly average. Demand is driven mainly by high-volume autoinjectors, biosimilar product launches and new therapy areas such as infectious diseases. Expansion of production capacity is progressing as planned: a high-capacity line in Solothurn is being commissioned and a fully automated high-bay warehouse in Schwerin has been completed. » Mere på finanzen.net
Ypsomed doubles dividend after profit surge

Following a marked rise in profits, Ypsomed increased its dividend and has now doubled it. The shift to a focused medical-technology and injection-systems provider improved its results. » Mere på finanzen.net

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2026 har YPSOMED N allerede udloddet 4,77 € i udbytte. Den seneste udlodning fandt sted i juli.

Virksomhedstal

I det seneste kvartal havde YPSOMED N en omsætning på 398,85 mio. € og et nettoresultat på 89,71 mio. €

(EUR)	marts 2026	YoY
Omsætning	398,85 mio.	-
Bruttofortjeneste	178,05 mio.	-
Nettoresultat	89,71 mio.	-
EBITDA	167,46 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	5,9 mia. €
Antal aktier	13,15 mio.
Højeste/laveste i 52 uger	453,97 € - 281,97 €
Udbytteafkast	1,11 %
Udbytte TTM	4,77 €
Beta	0,89
P/E (PE Ratio)	25,41
PEG (PEG Ratio)	0,25
K/I (PB Ratio)	7,50
P/S (PS Ratio)	7,45

Virksomhedsprofil

Ypsomed Holding AG og dets datterselskaber udvikler, fremstiller og sælger injektions- og infusionssystemer til farmaceutiske og bioteknologiske virksomheder. Selskabet opererer i to segmenter, Ypsomed Delivery Systems og Ypsomed Diabetes Care. Segmentet Ypsomed Delivery Systems leverer forskellige injektionssystemer, såsom pen-injektorer, auto-injektorer, plaster-injektorer og bærbare injektorer, samt andre smarte enheder. Dette segment tilbyder sine produkter under mærket YDS. Segmentet Ypsomed Diabetes Care sælger og handler med insulinpumper, infusionssæt, penkanyler, systemer til måling af blodsukker, tilbehør og andre dagligdags artikler til diabetikere. Dette segment tilbyder sine produkter under mærkenavnet mylife. Selskabet tilbyder præcisionsdrejede dele samt kontraktproduktion og andre tjenester. Det markedsfører sine produkter gennem bioteknologiske og farmaceutiske partnere, samt gennem sit eget distributionsnetværk og uafhængige distributører. Selskabet er aktivt i Schweiz, Europa, Nordamerika og internationalt. Ypsomed Holding AG blev grundlagt i 1984 og har hovedkontor i Burgdorf, Schweiz.